Novo Ventures follows dual investment approach
Managing partner Søren Carlsen spoke to MedWatch about Novo Ventures’ investment approach, which has seen the venture company raising its stake in a public, US-based company significantly.
BY STEFAN SINGH KAILAY
Novo Ventures has begun investing in publicly listed companies to a much larger extent than in the past as a part of a more strategic approach to the distribution of the DKK 1.2 billion (USD 205 million) it invests annually.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Novo Seeds in biggest ever licensing deal
For abonnenter
Novo kicks investments into next gear in 2014
For abonnenter
Novo heads capital injection in blood potassium company
For abonnenter
